Biotron Ltd
BIT
Company Profile
Business description
Biotron Ltd is an Australian biotechnology company focused on the development and commercialization of antiviral therapies and neuroscience-related products. The company reports two operating segments: SedRx, focused on anesthetic and neuroscience products, and Viron, which encompasses antiviral drug development programs. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.
Contact
66 Hunter Street
Level 2
SydneyNSW2000
AUST: +61 293003344
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
4
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
Consumer caution dents growth, shares look cheap.
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Income opportunities remain beneath the surface.
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Shares fell as investors digested the latest earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,128.60 | 173.70 | 1.94% |
| CAC 40 | 8,177.89 | 157.58 | 1.96% |
| DAX 40 | 26,437.67 | 573.05 | 2.22% |
| Dow JONES (US) | 53,356.12 | 1,569.40 | 3.03% |
| FTSE 100 | 10,829.21 | 190.78 | 1.79% |
| HKSE | 23,919.50 | 393.53 | 1.67% |
| NASDAQ | 25,736.51 | 364.50 | 1.44% |
| Nikkei 225 | 62,242.06 | 53.43 | 0.09% |
| NZX 50 Index | 14,053.05 | 269.60 | 1.96% |
| S&P 500 | 7,688.62 | 119.70 | 1.58% |
| S&P/ASX 200 | 8,991.50 | 157.00 | 1.78% |
| SSE Composite Index | 3,686.14 | 0.04 | -0.00% |